Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

Fractional Flow reserve (FFR) selection on the Abbott, St. Jude FFR system console. The TARGET FFR study at #TCT2020 #TCTconnect.
News | FFR Technologies | October 23, 2020
FFR-guided PCI Optimization Strategy May Lead to Improved Outcomes
October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided...
read more
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone actually was not flow limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings. #TCT2020 #TCTconnect

An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

News | FFR Technologies | October 22, 2020 | Dave Fornell, Editor
FFR-CT Did Not Significantly Reduce Costs But Reduced Rates of Invasive Coronary Angiography
October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from...
read more
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect

Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates.

Feature | Stents | October 22, 2020 | Dave Fornell, Editor
Durable Polymer Drug-Eluting Stents Perform Better Than Biodegradable Polymer DES
October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable...
read more
For patients undergoing percutaneous coronary intervention (PCI), treatment with the CeloNova Biosciences nanotechnology polymer-coated Cobra PzF stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy. #TCT #TCTconnect #TCT2020
News | Stents | October 22, 2020
Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-inferiority for Thrombotic Events
October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology...
read more
Videos | Coronavirus (COVID-19) | October 20, 2020
VIDEO: Use of Impella in COVID-19 Patients
Chuck Simonton, M.D., chief medical officer at Abiomed, explains when advanced hemodynamic support in required in COVID...
read more
Videos | Hemodynamic Support Devices | October 20, 2020
VIDEO: Abiomed Highlights Trends and New Technology in Hemodynamic Support
Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the...
read more
Videos | Cath Lab | October 19, 2020
VIDEO: Intravascular Lithotripsy to Treat Severely Calcified Coronary Artery Lesions
Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ...
read more
Videos | Stents Drug Eluting | October 19, 2020
VIDEO: Results of the OPTIMIZE IDE Trial for the Svelte Drug Eluting Stent 
Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ...
read more
Videos | Antiplatelet and Anticoagulation Therapies | October 19, 2020
VIDEO: Crushing Prasugrel Tablets Does Not Help STEMI Patients
The COMPARE CRUSH Trial looked at the effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned...
read more
Videos | Heart Valve Technology | October 19, 2020
VIDEO: Results Mixed on Use of Cerebral Embolic Protection in TAVR From the STS/ACC TVT Registry
David Cohen, M.D., presents late-breaking data from the STS/ACC Transcatheter Valve Registry (TVT) showing the impact...
read more
Videos | Antiplatelet and Anticoagulation Therapies | October 19, 2020
VIDEO: Use of Shorten DAPT and the Xience Stent in High-bleeding Risk Patients
Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use...
read more
Videos | Heart Valve Technology | October 19, 2020
VIDEO: General vs Local Anesthesia for TAVR Addressed in SOLVE-TAVI Trial
Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local...
read more
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit...
read more
The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the safety and effectiveness of the Medtronic  IN.PACT 0.014 drug-coated balloon (DCB) in critical limb ischemia (CLI) subjects with chronic total occlusion (CTO) in the infrapopliteal arteries. The data were presented in the Late-Breaking Clinical Trial Sessions at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual symposium of the Cardiovascular Research Foundation (CRF). #TCTconnect #TCT2020
News | Drug-Eluting Balloons | October 18, 2020
Drug-coated Balloon for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia
October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the...
read more
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
Combined FFR and OCT Imaging Can Improve Accuracy of High-Risk Lesion Identification in Patients With Diabetes
October 18, 2020 – Data from the COMBINE (OCT-FFR) study found that the use of FFR combined with OCT imaging can help...
read more
© Copyright Wainscot Media. All Rights Reserved.